Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An Adaptive, Open-Label, Dose-Finding Phase 1/2 Study of Rilzabrutinib in Relapsed Immune Thrombocytopenia
2023-509397-39-00Phase 2Completed
- Sponsor
- Principia Biopharma
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Principia Biopharma. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) - Parts A and B, Consecutive increased platelet counts - Part A and 1 more. Started Feb 2024; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2023-509397-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509397-39-00.